Minerva Neurosciences (NERV) Income towards Parent Company (2013 - 2026)
Minerva Neurosciences (NERV) posted Income towards Parent Company of -$32.3 million for Q1 2026, down 466.37% on a QoQ basis from -$5.7 million in Q4 2025, and down 762.9% year-over-year from $4.9 million in Q1 2025.
Minerva Neurosciences (NERV) Income towards Parent Company (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Income towards Parent Company history runs 14 years deep, the most recent figure standing at -$32.3 million for Q1 2026.
- Quarterly Income towards Parent Company fell 762.9% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.0 million (down 143.59% YoY) and the FY2025 annual result came in at -$113.8 million, up 2.4% from the prior year.
- Income towards Parent Company was -$32.3 million for Q1 2026 at Minerva Neurosciences, down from -$5.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$2.7 million in Q3 2025 and bottomed at -$103.7 million in Q4 2023.
- A 5-year average of -$18.0 million and a median of -$5.9 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2024 — Income towards Parent Company soared 95.83% — and 2026, when it slumped 762.9%.
- Minerva Neurosciences' Income towards Parent Company stood at -$94.9 million in 2022, then decreased by 9.27% to -$103.7 million in 2023, then surged by 95.83% to -$4.3 million in 2024, then slumped by 31.8% to -$5.7 million in 2025, then sank by 466.37% to -$32.3 million in 2026.
- Business Quant data shows NERV's Income towards Parent Company at -$32.3 million in Q1 2026, -$5.7 million in Q4 2025, and -$2.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Minerva Neurosciences | 185.26 Mn | 185.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.31 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | -3.74 Mn |
| Dec 31, 2024 | -4.33 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -5.93 Mn |
| Mar 31, 2024 | -6.32 Mn |
| Dec 31, 2023 | -103.68 Mn |
| Sep 30, 2023 | -6.77 Mn |
| Jun 30, 2023 | -6.18 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -94.88 Mn |
| Sep 30, 2022 | -5.66 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | -8.04 Mn |
| Dec 31, 2021 | -21.37 Mn |
| Sep 30, 2021 | -7.71 Mn |
| Jun 30, 2021 | -8.98 Mn |